Romiplostim
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Romiplostim |
| DrugBank ID | DB05332 |
| Brand Names (EU) | Nplate |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Adults: Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Paediatrics: Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 100.00% | DL |
| 2 | pseudo-von Willebrand disease | 100.00% | DL |
| 3 | Glanzmann thrombasthenia | 100.00% | DL |
| 4 | fetal and neonatal alloimmune thrombocytopenia | 99.99% | DL |
| 5 | Scott syndrome | 99.97% | DL |
| 6 | hemorrhagic disorder due to a constitutional thrombocytopenia | 99.95% | DL |
| 7 | bleeding diathesis due to a collagen receptor defect | 99.95% | DL |
| 8 | platelet-type bleeding disorder | 99.93% | DL |
| 9 | autosomal dominant macrothrombocytopenia | 99.88% | DL |
| 10 | Ehlers-Danlos syndrome, fibronectinemic type | 99.85% | DL |
| 11 | paroxysmal nocturnal hemoglobinuria | 99.64% | DL |
| 12 | proteinuria | 99.58% | DL |
| 13 | neurolymphomatosis | 99.57% | DL |
| 14 | mixed-type autoimmune hemolytic anemia | 99.56% | DL |
| 15 | drug-induced autoimmune hemolytic anemia | 99.53% | DL |
| 16 | neonatal autoimmune hemolytic anemia | 99.49% | DL |
| 17 | plasmacytoma | 99.49% | DL |
| 18 | primary CD59 deficiency | 99.44% | DL |
| 19 | Peyronie disease | 99.34% | DL |
| 20 | cold agglutinin disease | 99.26% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.